A recently published study reported that high serum ApoB/ApoA-1 level increases the risk of adverse cardiovascular events. Elevated levels of ApoA-1 could have a protective role in reducing the risk. International guidelines for treating hyperlipidemia recommend monitoring low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B (Apo B) for cardiac risk detection. However, it does not advise monitoring of apolipoprotein A-1 (ApoA-1) level.
ApoB and ApoA-1 have antagonistic roles in atherogenesis; therefore, their levels can reflect the balance of atherogenic and anti-atherogenic particles in serum. A recent study published in the journal Plos Medicine, ascertains the significance of the ApoB/ApoA-1 ratio as a single value in anticipating forthcoming cardiovascular events. Key findings Individuals with MACE showed a higher ApoB/ApoA-1 ratio than controls two decades…
